CTLA4 and neoplasm: This site-specific delivery increased tumor infiltrating lymphocytes, resulted in superior tumor growth inhibition, arrested metastatic spread, and induced complete anti-tumor responses when compared with systemic anti-CTLA-4 antibody administration.